Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Milani

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Expert Opinion on Pharmacotherapy|September 19, 2012
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancerFilippo Montemurro, Valentina Rossi, Elena Geuna, et al.
Expert Opinion on Pharmacotherapy|January 7, 2011
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Elena Geuna, Andrea Milani, Stefania Redana, et al.
Expert Opinion on Investigational Drugs|February 12, 2016
Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancerRossella Martinello, Andrea Milani, Elena Geuna, et al.
Expert Opinion on Investigational Drugs|February 4, 2015
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancerElena Geuna, Andrea Milani, Rossella Martinello, et al.
Plos Pathogens|February 10, 2011
Positive signature-tagged mutagenesis in Pseudomonas aeruginosa: tracking patho-adaptive mutations promoting airways chronic infectionIrene Bianconi, Andrea Milani, Cristina Cigana, et al.
Molecular Microbiology|January 14, 2009
Transcriptional wiring of the TOL plasmid regulatory network to its host involves the submission of the sigma54-promoter Pu to the response regulator PprAElena Vitale, Andrea Milani, Francesco Renzi, et al.
Expert Opinion on Pharmacotherapy|September 21, 2016
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancerRossella Martinello, Sofia Genta, Danilo Galizia, et al.
Genes|November 27, 2021
Target-Site Mutations and Expression of <i>ALS</i> Gene Copies Vary According to <i>Echinochloa</i> SpeciesSilvia Panozzo, Elisa Mascanzoni, Laura Scarabel, et al.
Pest Management Science|July 29, 2023
Genetic basis and origin of resistance to acetolactate synthase inhibitors in Amaranthus palmeri from Spain and ItalyAlfredo Manicardi, Laura Scarabel, Josep María Llenes, et al.
Expert Review of Anticancer Therapy|May 5, 2015
Linifanib: current status and future potential in cancer therapyCaterina Aversa, Francesco Leone, Giorgia Zucchini, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|September 19, 2012
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancerFilippo Montemurro, Valentina Rossi, Elena Geuna, et al.
Expert Opinion on Pharmacotherapy|January 7, 2011
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Elena Geuna, Andrea Milani, Stefania Redana, et al.
Expert Opinion on Investigational Drugs|February 12, 2016
Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancerRossella Martinello, Andrea Milani, Elena Geuna, et al.
Expert Opinion on Investigational Drugs|February 4, 2015
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancerElena Geuna, Andrea Milani, Rossella Martinello, et al.
Plos Pathogens|February 10, 2011
Positive signature-tagged mutagenesis in Pseudomonas aeruginosa: tracking patho-adaptive mutations promoting airways chronic infectionIrene Bianconi, Andrea Milani, Cristina Cigana, et al.
Molecular Microbiology|January 14, 2009
Transcriptional wiring of the TOL plasmid regulatory network to its host involves the submission of the sigma54-promoter Pu to the response regulator PprAElena Vitale, Andrea Milani, Francesco Renzi, et al.
Expert Opinion on Pharmacotherapy|September 21, 2016
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancerRossella Martinello, Sofia Genta, Danilo Galizia, et al.
Genes|November 27, 2021
Target-Site Mutations and Expression of <i>ALS</i> Gene Copies Vary According to <i>Echinochloa</i> SpeciesSilvia Panozzo, Elisa Mascanzoni, Laura Scarabel, et al.
Pest Management Science|July 29, 2023
Genetic basis and origin of resistance to acetolactate synthase inhibitors in Amaranthus palmeri from Spain and ItalyAlfredo Manicardi, Laura Scarabel, Josep María Llenes, et al.
Expert Review of Anticancer Therapy|May 5, 2015
Linifanib: current status and future potential in cancer therapyCaterina Aversa, Francesco Leone, Giorgia Zucchini, et al.
Pageof 4